In its recently released study of the global nebulizer market, Cambridge Consulting named PARI, Midlothian, Va, the market dominator for high-end, differentiated nebulizers in the United States and Germany. This follows the September Frost & Sullivan Product Differentiation Innovation Award for PARI’s TREK compressor nebulizer system.
Cambridge Consulting’s 2006 survey noted that global nebulizer market revenues are expected to grow from $288.5 million to $398.4 million in 2110. In the two largest markets in Europe and the Americas, PARI was named the market leader for differentiated nebulizers mainly used to treat asthma, COPD, and cystic fibrosis.

“Every day we are developing new and improved products for a wide variety of diseases and are pleased that the market prefers our nebulizer and compressor systems for respiratory therapies,” said Werner Gutmann, president of PARI Respiratory Equipment.